Skip to Content
Merck
All Photos(1)

Key Documents

View All Documentation

O0700000

Oxytocin

European Pharmacopoeia (EP) Reference Standard

Synonym(s):

α-Hypophamine, Oxytocic hormone

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C43H66N12O12S2
CAS Number:
50-56-6
Molecular Weight:
1007.19
Beilstein:
3586108
MDL number:
MFCD00076731
UNSPSC Code:
41116107
PubChem Substance ID:
329818890
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

oxytocin

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

SMILES string

[H]N[C@H]1CSSC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc2ccc(O)cc2)NC1=O)[C@@H](C)CC)C(=O)N3CCC[C@H]3C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O

InChI

1S/C43H66N12O12S2/c1-5-22(4)35-42(66)49-26(12-13-32(45)57)38(62)51-29(17-33(46)58)39(63)53-30(20-69-68-19-25(44)36(60)50-28(40(64)54-35)16-23-8-10-24(56)11-9-23)43(67)55-14-6-7-31(55)41(65)52-27(15-21(2)3)37(61)48-18-34(47)59/h8-11,21-22,25-31,35,56H,5-7,12-20,44H2,1-4H3,(H2,45,57)(H2,46,58)(H2,47,59)(H,48,61)(H,49,66)(H,50,60)(H,51,62)(H,52,65)(H,53,63)(H,54,64)/t22-,25-,26-,27-,28-,29-,30-,31-,35-/m0/s1

InChI key

XNOPRXBHLZRZKH-DSZYJQQASA-N

Gene Information

human ... OXTR(5021)

Looking for similar products? Visit Product Comparison Guide

Related Categories

Amino Acid Sequence

Cys-Tyr-Ile-Gln-Asn-Cys-Pro-Leu-Gly-NH2 [Disulfide Bridge: 1-6]

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Oxytocin EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Biochem/physiol Actions

Stimulates uterine contraction and lactation; increases Na+ excretion; stimulates myometrial GTPase and phospholipase C.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Y Aoki et al.
Molecular psychiatry, 20(4), 447-453 (2014-07-30)
The neuropeptide oxytocin may be an effective therapeutic strategy for the currently untreatable social and communication deficits associated with autism. Our recent paper reported that oxytocin mitigated autistic behavioral deficits through the restoration of activity in the ventromedial prefrontal cortex
Mikko J Peltola et al.
Emotion (Washington, D.C.), 14(3), 469-477 (2014-04-23)
Recent studies suggest that parental caregiving is associated with adaptive changes in neurocognitive responses to emotional cues and oxytocin function, possibly reflecting the increased need of parents to monitor infants' emotional states. In the current study, we investigated whether the
Gül Dölen et al.
Nature, 501(7466), 179-184 (2013-09-13)
Social behaviours in species as diverse as honey bees and humans promote group survival but often come at some cost to the individual. Although reinforcement of adaptive social interactions is ostensibly required for the evolutionary persistence of these behaviours, the
Elizabeth C Finger et al.
Neurology, 84(2), 174-181 (2014-12-17)
To determine the safety and tolerability of 3 doses of intranasal oxytocin (Syntocinon; Novartis, Bern, Switzerland) administered to patients with frontotemporal dementia (FTD). We conducted a randomized, parallel-group, double-blind, placebo-controlled study using a dose-escalation design to test 3 clinically feasible
Dong Bo Li et al.
Organic letters, 15(18), 4766-4769 (2013-09-03)
New classes of thia/oxa-azaspiro[3.4]octanes are synthesized through the implementation of robust and step-economic routes. The targeted spirocycles have been designed to act as novel, multifunctional, and structurally diverse modules for drug discovery. Furthermore, enantioselective approaches to the spirocycles are reported.
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service